Earnings Summary

Biomarin Pharmaceutical Inc.’s revenue jumped 109325.49% since last year same period to $648833Mn in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 100306.37% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit jumped 174253.02% since last year same period to $88662Mn in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 435050.92% jump in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin jumped 59.33% since last year same period to 13.66% in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 333.39% jump in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s price-to-earnings ratio after this Q1 2024 earnings stands at 105.82.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.34 - a 47.83% jump from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.34.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biomarin Pharmaceutical Inc.’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biomarin Pharmaceutical Inc.’s return on equity (ROE) stands at 0.04.